Systemtherapie des Ovarialkarzinoms bei einem Rezidiv: Teil 2 : Leitthema
Vascular endothelial growth factor A (VEGF-A) is crucial for tumor progression in ovarian cancer and plays a key role in the development of malignant ascites. The rationale for therapeutically inhibiting angiogenesis is therefore obvious. By binding to VEGF, bevacizumab neutralizes its biological ac...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article (Journal) |
| Language: | German |
| Published: |
August 2025
|
| In: |
Die Onkologie
Year: 2025, Volume: 31, Issue: 8, Pages: 787-799 |
| ISSN: | 2731-7234 |
| DOI: | 10.1007/s00761-025-01765-6 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s00761-025-01765-6 Verlag, lizenzpflichtig, Volltext: http://link.springer.com/article/10.1007/s00761-025-01765-6 
|
| Author Notes: | Frederik Marmé |
| Summary: | Vascular endothelial growth factor A (VEGF-A) is crucial for tumor progression in ovarian cancer and plays a key role in the development of malignant ascites. The rationale for therapeutically inhibiting angiogenesis is therefore obvious. By binding to VEGF, bevacizumab neutralizes its biological activity. This decreases tumor vascularization and, thus, inhibits tumor growth. Results from two randomized phase III trials are available for patients with platinum-sensitive recurrence. In these studies, bevacizumab plus platinum-containing combination chemotherapy and the subsequent administration of bevacizumab maintenance therapy were investigated in comparison to chemotherapy alone. The result of both studies was a significant increase in progression-free survival (PFS) in favor of the bevacizumab combination. Based on these results, bevacizumab was approved in Europe for use in combination with carboplatin/gemcitabine and carboplatin/paclitaxel. A study also showed a significant difference in PFS in patients with relapse for whom platinum is not a suitable treatment option. The European Medicines Agency (EMA) has therefore approved bevacizumab in combination with paclitaxel, pegylated liposomal doxorubicin (PLD), or topotecan. The efficacy of platinum-free monochemotherapy in combination with bevacizumab in platinum-resistant relapse was confirmed in a further study. In addition to clinical development of new antibody-drug conjugates, new targeted treatment approaches and treatment with poly(ADP-ribose) polymerase (PARP) inhibitors and immune checkpoint inhibitors are also presented. |
|---|---|
| Item Description: | Online publiziert: 17. Juli 2025 Gesehen am 11.09.2025 |
| Physical Description: | Online Resource |
| ISSN: | 2731-7234 |
| DOI: | 10.1007/s00761-025-01765-6 |